Dentsply Sirona Debuts FDA-Cleared AI Diagnostic Boosting PARL Detection 46%
Dentsply Sirona launched Smart View – Detect, the world’s first FDA-cleared AI-enabled aid for detecting periapical radiolucencies in CBCT scans. Internal study showed a 46% increase in PARL detection sensitivity without more false positives; the feature launches May 12 via DS Core on existing Orthophos S, SL and Axeos systems.
1. Smart View – Detect Launch
Dentsply Sirona has introduced Smart View – Detect, the first AI-driven diagnostic tool cleared by the FDA for identifying periapical radiolucencies (PARLs) in CBCT scans. The solution integrates into the DS Core platform and is also CE approved for European markets.
2. Clinical Study Results
An internal multi-reader, multi-case study demonstrated a roughly 46% relative increase in tooth-level PARL detection sensitivity when using the AI aid versus unaided review, without a significant rise in false positives. This enhancement aims to reduce overlooked findings and improve diagnostic confidence.
3. Availability and Integration
Smart View – Detect will be available starting May 12 via DS Core subscriptions and is compatible with existing Orthophos S, Orthophos SL and Axeos CBCT systems. No additional hardware purchases are required for current CBCT users enrolled in DS Core Standard or Advanced tiers.
4. Practice Implications
By highlighting potential PARL regions directly on CBCT scans, the AI feature supports more efficient image review and clearer patient communication. This innovation could drive increased DS Core adoption, strengthen Dentsply Sirona’s digital dentistry offerings and potentially boost recurring subscription revenue.